| 词条 | Inverse benefit law |
| 释义 |
The inverse benefit law states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively a drug is marketed. Two Americans, Howard Brody and Donald Light, have defined the inverse benefit law, inspired by Tudor Hart's inverse care law.[1] A drug effective for a serious disorder is less and less effective as it is promoted for milder cases and for other conditions for which the drug was not approved. Although effectiveness becomes more diluted, the risks of harmful side effects persist, and thus the benefit-harm ratio worsens as a drug is marketed more widely. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing.[1] State of affairsThe law is manifested through 6 basic marketing strategies:
ImpactThis is the reason why organizations like "Worst Pill, Best Pill" [2] recommend not to use/prescribe new medications before being in the market for at least ten years (except in the case of important new drugs that treat previously unsolved problems). Agencies of drugs, committee of ethics and organizations of patients' safety should consider:
See also{{col div}}
References1. ^1 {{cite journal |doi=10.2105/AJPH.2010.199844 |pmid=21233426 |pmc=3036704 |title=The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health |journal=American Journal of Public Health |volume=101 |issue=3 |pages=399–404 |year=2011 |last1=Brody |first1=Howard |last2=Light |first2=Donald W }} 2. ^{{cite web|url=http://www.worstpills.org/ |title=Worst Pill, Best Pill. Public Citizen's Health Research Group |publisher=Worstpills.org |date= |accessdate=2014-02-17}} 3. ^{{cite journal |doi=10.1001/jama.281.18.1753 |pmid=10328077 |title=The Safety of New Medicines |journal=JAMA |volume=281 |issue=18 |pages=1753–4 |year=1999 |last1=Wood |first1=Alastair J. J }} 4. ^{{cite web|url=http://english.prescrire.org/en/81/168/46799/0/NewsDetails.aspx |title=Astellas' lawsuit against Prescrire: French court rules that Prescrire did not "denigrate" Protopic° (tacrolimus). Prescrire. 2 March 2011 |publisher=English.prescrire.org |date=2011-03-02 |accessdate=2014-02-17}} 5. ^Gérvas J. Garum. Acta Sanitaria. 07/03/2011. Bibliography
External links
3 : Pharmaceutics|Health economics|Pharmaceutical industry |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。